SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022

Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.

CordenPharma Increases xRNA-based Capabilities with a Strategic Investment in LNP Formulation Services at its Caponago Injectable Facility June 1, 2022

CordenPharma has recently increased its xRNA capabilities at its sterile injectable facility in Caponago, Italy. The company reports that it is investing over €10M in new Lipid Nanoparticle (LNP) formulation,….

APTAMER TECHNOLOGY - From Postal Codes to GPS: Building Better Drug Conjugates With Aptamers November 30, 2021

David Bunka, PhD, and Emily Robinson, PhD, focus on a new breed of affinity binders that can be used as an alternative to antibody therapeutics and has the potential to reshape the industry, delivering new medicines with improved safety and efficacy profiles and reduced healthcare costs.

SOTIO Expands Its Antibody-Drug Conjugate Pipeline With Exclusive Collaboration & License Agreement With LegoChem Biosciences November 16, 2021

SOTIO Biotech recently announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc in which SOTIO will obtain rights to deploy LCB’s ADC technology for up to….

SPECIAL FEATURE - Injection Devices: Designing Simplicity, Safety & Adherence Into One Delivery System August 26, 2021

Contributor Cindy Dubin, in this annual report, speaks with industry innovators and takes a deep dive into the myriad injectables that are currently in development or recently introduced to the market.

GENE THERAPY - Solving the Puzzle: Aligning the Pieces of Gene Therapy & Creating Success for Patients August 26, 2021

Sue Washer, MBA, reviews the various elements that must come together in developing safe, effective, and commercially viable viral-based gene therapies.

PLATFORM TECHNOLOGY - Overcoming the Challenges of Drug Brain Delivery With a Novel Brain Delivery Vector November 23, 2020

Mei Mei Tian, PhD, explains how the xB3 platform has the potential to support development of treatments for CNS diseases that can treat thousands of patients in the years ahead.

NEXT-GENERATION TUMOR TARGETING - Leveraging the Tumor Microenvironment to Change the Standard of Care June 4, 2020

Vishwas Paralkar, PhD, highlights a unique platform technology that represents the first technology that has successfully been used to target cancer drugs to tumor cells in animal models, while sparing healthy tissue.

Triphase Accelerator & Catalent Announce Interim Results of a Dose Escalation Phase 1 Clinical Trial May 19, 2020

SPECIAL FEATURE - Injection Devices: Wearables, Connectivity & Patient-Centric Designs Empower Self-Administration September 3, 2019

Contributor Cindy H. Dubin highlights the innovation in injection devices – from wearables to connectivity to varied dose administration – that have occurred in the past year.

SPECIAL FEATURE - Prefilled Syringes & Parenteral Manufacturing: Flexibility for Faster Development April 30, 2019

Contributor Cindy H. Dubin interviews several contract manufacturers and device developers who are responsible for creating next-generation parenteral drug delivery.

BioAtla & BeiGene Form Worldwide Development & Commercialization Collaboration April 9, 2019

BioAtla , LLC and BeiGene, Ltd. recently announced the two companies have entered into a global co-development and collaboration agreement for the development, manufacturing, and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071).

NANOPARTICLE DELIVERY - Ultra-Small Particles Offer Big Hope in Cancer Theranostics February 28, 2019

Kai Ma, PhD, Ulrich Wiesner, and Michelle Bradbury, MD, PhD, believe ultra-small sub-10 nm particles hold unique properties and represent an emerging area of investigation for biomedical applications.

ANTIBODY DRUG CONJUGATES - Expansion of Approved Indications Backs 25% Increase in Global Market October 1, 2018

Laurie L. Sullivan and Shalini Shahani Dewan, MS, believe technological advancements, the rising incidence of cancer, and an increasing demand for biologic therapies are all factors driving growth in the global ADC market.

Telix Completes Acquisition of Atlab for Prostate Cancer Program September 13, 2018

INJECTABLE NANOMEDICINES - New Developments in Long-Acting Injectable Nanoformulations May 22, 2018

Dongwei Guo, PhD, and Jingjun Huang, PhD, focus on the overview of nanoproducts in the market and the technologies to make long-acting injectable nanoformulations.

SPECIAL FEATURE - Formulation Development & Manufacturing - CDMOs Offer Speed, Advanced Technologies, & the Ability to Handle More Potent APIs April 4, 2017

Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs.

SPECIAL FEATURE - Platform Technologies: Not Just for Big Pharma October 3, 2016

Contributor Cindy H. Dubin recently spoke with several companies that are debunking the theory that access to the latest technological platforms to aid efficient drug discovery and development is limited to Big Pharma, which can more easily justify the costs of creating and operating innovative platforms.

NANOTECHNOLOGY MARKET - Nanotechnology Markets in Healthcare & Medicine November 19, 2014

Kevin James, Jackson Highsmith, and Paul Evers report the global market for nanoparticles in the life sciences is estimated at over $29.6 billion for 2014. This market is forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate of 22%. The biggest increase will come in the area of drug delivery systems.

SPECIAL FEATURE - Injectable Drug Delivery: Safer, Simpler, Smarter Devices September 4, 2014

Contributor Cindy H. Dubin speaks with some of the leading companies operating in the injectables arena, and discovers this ever-evolving sector is witnessing some very specific and eye-opening trends that are affecting the market’s growth.